AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

AstraZeneca88 enrolled

Overview

The purpose of this study is to assess the effect and safety of AZD6244(ARRY-142886)versus pemetrexed in the second or third line treatment of advanced Non-Small Cell Lung Cancer. Following baseline assessments, a minimum of 64 patients in approximately 5-6 centers from the US will be treated with either AZD6244 or pemetrexed. Treatment will be continued for as long as patients receive clinical benefit.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-small Cell Lung Cancer

Interventions

AZD6244DRUG

oral vial

PemetrexedDRUG

oral

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with non-small cell lung cancer * Previously received one or two chemotherapeutic treatments Exclusion Criteria: * Previous therapy with MEK inhibitor or pemetrexed * Any recent surgery, unhealed surgical incision or severe condition such as uncontrolled cardiac disease or chronic gastrointestinal diseases

Locations (8)

Research Site

Los Angeles, California, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

New York, New York, United States

Research Site

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

Assess tumor growth

Time frame: assessed every 12 weeks

Secondary Outcomes

Assess safety and tolerability of AZD6244

Time frame: assessed at each visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.